$RKDA
Arcadia Biosciences, Inc.

2017 Q1 Form 10-K Financial Statement

#000156459017003724 Filed on March 08, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q4 2016
Revenue $1.018M $540.0K $3.188M
YoY Change 19.48% -60.0% -41.12%
Cost Of Revenue $106.0K $650.0K $895.0K
YoY Change -27.89% -2.99% 0.34%
Gross Profit $912.0K -$110.0K $2.293M
YoY Change 29.36% -116.18% -49.29%
Gross Profit Margin 89.59% -20.37% 71.93%
Selling, General & Admin $3.052M $3.370M $12.25M
YoY Change -11.18% 17.01% 10.17%
% of Gross Profit 334.65% 534.23%
Research & Development $1.823M $1.990M $8.663M
YoY Change -17.21% 6.42% -3.38%
% of Gross Profit 199.89% 377.8%
Depreciation & Amortization $80.00K $70.00K $300.0K
YoY Change 14.29% -12.5% 3.45%
% of Gross Profit 8.77% 13.08%
Operating Expenses $4.981M $5.360M $21.81M
YoY Change -13.9% 12.84% 3.96%
Operating Profit -$3.963M -$5.470M -$18.62M
YoY Change -19.66% 34.4% 19.64%
Interest Expense $339.0K -$330.0K $1.319M
YoY Change 3.67% -49.23% -50.38%
% of Operating Profit
Other Income/Expense, Net $96.00K $100.0K $340.0K
YoY Change 26.32% -88.89% -34.74%
Pretax Income -$4.206M -$5.710M -$19.60M
YoY Change -18.87% 40.99% 9.31%
Income Tax $10.00K $0.00 $25.00K
% Of Pretax Income
Net Earnings -$4.216M -$5.710M -$19.62M
YoY Change -18.77% 47.93% 9.29%
Net Earnings / Revenue -414.15% -1057.41% -615.56%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.901M -$2.572M -$8.838M
COMMON SHARES
Basic Shares Outstanding 44.51M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2016 Q4 2016
SHORT-TERM ASSETS
Cash & Short-Term Investments $48.53M $50.56M $50.56M
YoY Change -3.31% 0.64% 0.64%
Cash & Equivalents $7.559M $2.013M $2.010M
Short-Term Investments $40.97M $48.55M $48.55M
Other Short-Term Assets $1.280M $880.0K $880.0K
YoY Change -3.76% 27.54% 27.54%
Inventory $240.0K $250.0K $250.0K
Prepaid Expenses
Receivables $400.0K $530.0K $530.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $50.44M $52.22M $52.22M
YoY Change -4.0% 0.39% 0.38%
LONG-TERM ASSETS
Property, Plant & Equipment $490.0K $510.0K $510.0K
YoY Change -25.76% -12.82% -13.56%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $2.500M $2.500M
YoY Change -100.0% -87.34% -87.34%
Other Assets $1.720M $19.00K $1.350M
YoY Change -14.43% -24.0% -28.57%
Total Long-Term Assets $2.210M $4.354M $4.350M
YoY Change -87.42% -80.41% -80.42%
TOTAL ASSETS
Total Short-Term Assets $50.44M $52.22M $52.22M
Total Long-Term Assets $2.210M $4.354M $4.350M
Total Assets $52.65M $56.57M $56.57M
YoY Change -24.9% -23.8% -23.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $20.00K $30.00K $250.0K
YoY Change 100.0% -93.18% -43.18%
Accrued Expenses $2.140M
YoY Change 7.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.083M $0.00
YoY Change
Total Short-Term Liabilities $5.170M $3.130M $3.130M
YoY Change 24.28% -9.28% -9.28%
LONG-TERM LIABILITIES
Long-Term Debt $23.09M $25.13M $25.13M
YoY Change -7.55% 0.79% 0.8%
Other Long-Term Liabilities $6.010M $3.000M $6.120M
YoY Change 9.47% 0.0% 8.51%
Total Long-Term Liabilities $23.09M $28.13M $31.25M
YoY Change -7.55% 0.71% 2.22%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.170M $3.130M $3.130M
Total Long-Term Liabilities $23.09M $28.13M $31.25M
Total Liabilities $34.28M $34.38M $34.38M
YoY Change -1.01% 1.06% 1.06%
SHAREHOLDERS EQUITY
Retained Earnings -$151.6M
YoY Change 14.88%
Common Stock $173.8M
YoY Change 0.87%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.37M $22.20M $22.20M
YoY Change
Total Liabilities & Shareholders Equity $52.65M $56.57M $56.57M
YoY Change -24.9% -23.8% -23.8%

Cashflow Statement

Concept 2017 Q1 2016 Q4 2016
OPERATING ACTIVITIES
Net Income -$4.216M -$5.710M -$19.62M
YoY Change -18.77% 47.93% 9.29%
Depreciation, Depletion And Amortization $80.00K $70.00K $300.0K
YoY Change 14.29% -12.5% 3.45%
Cash From Operating Activities -$4.530M -$4.280M -$17.06M
YoY Change -6.79% 8.35% 12.91%
INVESTING ACTIVITIES
Capital Expenditures $57.00K -$10.00K $231.0K
YoY Change -58.39% -85.71% 52.98%
Acquisitions
YoY Change
Other Investing Activities $10.12M -$4.190M -$5.070M
YoY Change -3.34% -88.0% -89.03%
Cash From Investing Activities $10.06M -$4.200M -$5.300M
YoY Change -2.61% -88.0% -88.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 20.00K 20.00K 400.0K
YoY Change -77.78% -133.33% -99.42%
NET CHANGE
Cash From Operating Activities -4.530M -4.280M -17.06M
Cash From Investing Activities 10.06M -4.200M -5.300M
Cash From Financing Activities 20.00K 20.00K 400.0K
Net Change In Cash 5.550M -8.460M -21.96M
YoY Change -0.18% -78.31% -396.76%
FREE CASH FLOW
Cash From Operating Activities -$4.530M -$4.280M -$17.06M
Capital Expenditures $57.00K -$10.00K $231.0K
Free Cash Flow -$4.587M -$4.270M -$17.29M
YoY Change -8.2% 10.05% 13.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2016 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2016 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2016 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2015 us-gaap Licenses Revenue
LicensesRevenue
1216000
CY2016 dei Document Type
DocumentType
10-K
CY2016 dei Amendment Flag
AmendmentFlag
false
CY2016 dei Document Period End Date
DocumentPeriodEndDate
2016-12-31
CY2016 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
CY2016 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2016 dei Trading Symbol
TradingSymbol
RKDA
CY2016 dei Entity Registrant Name
EntityRegistrantName
ARCADIA BIOSCIENCES, INC.
CY2016 dei Entity Central Index Key
EntityCentralIndexKey
0001469443
CY2016 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2016 us-gaap Licenses Revenue
LicensesRevenue
144000
CY2015 us-gaap Contracts Revenue
ContractsRevenue
3732000
CY2016 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12250000
CY2016 us-gaap Contracts Revenue
ContractsRevenue
2375000
CY2016 us-gaap Sales Revenue Net
SalesRevenueNet
3188000
CY2015 us-gaap Sales Revenue Net
SalesRevenueNet
5414000
CY2017Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
44508709
CY2016Q2 dei Entity Public Float
EntityPublicFloat
18700000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23973000
CY2016Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
173723000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
172222000
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-151550000
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-131926000
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-19000
CY2015Q4 us-gaap Short Term Investments
ShortTermInvestments
26270000
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
706000
CY2015Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
82000
CY2015Q4 us-gaap Inventory Net
InventoryNet
294000
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
692000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
52017000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
585000
CY2015Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
1867000
CY2016Q4 us-gaap Long Term Investments
LongTermInvestments
2498000
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
19000
CY2016Q4 us-gaap Assets
Assets
56574000
CY2016Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2359000
CY2016Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
30000
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
740000
CY2015Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1008000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3450000
CY2016Q4 us-gaap Notes Payable To Bank Noncurrent
NotesPayableToBankNoncurrent
25127000
CY2015Q4 us-gaap Notes Payable To Bank Noncurrent
NotesPayableToBankNoncurrent
24930000
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
44000
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
44000
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-115000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
22198000
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
56574000
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44487678
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44184195
CY2016Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44487678
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44184195
CY2016 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
669000
CY2015 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
466000
CY2016 us-gaap Cost Of Goods Sold
CostOfGoodsSold
895000
CY2015 us-gaap Cost Of Goods Sold
CostOfGoodsSold
892000
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8663000
CY2015 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8966000
CY2015 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11119000
CY2016 us-gaap Operating Expenses
OperatingExpenses
21808000
CY2015 us-gaap Operating Expenses
OperatingExpenses
20977000
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-18620000
CY2015 us-gaap Operating Income Loss
OperatingIncomeLoss
-15563000
CY2016 us-gaap Interest Expense
InterestExpense
1319000
CY2015 us-gaap Interest Expense
InterestExpense
2658000
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
340000
CY2015 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
521000
CY2015 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-230000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19599000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17930000
CY2016 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
25000
CY2015 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
26000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-19624000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-17956000
CY2015 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
2574000
CY2015 rkda Deemed Dividends Warrant
DeemedDividendsWarrant
197000
CY2016 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19624000
CY2015 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20727000
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2015 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.73
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
44366816
CY2015 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
28559119
CY2016 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
96000
CY2015 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-115000
CY2016 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
96000
CY2015 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-115000
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19528000
CY2015 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20842000
CY2016 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
0
CY2015 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
91000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
-84766000
CY2015 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
361000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1392000
CY2015 us-gaap Temporary Equity Accretion To Redemption Value
TemporaryEquityAccretionToRedemptionValue
-2574000
CY2015 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
85455000
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
58428000
CY2015 rkda Deemed Dividends To Common Stock Warrant Holder
DeemedDividendsToCommonStockWarrantHolder
197000
CY2015 rkda Adjustments To Additional Paid In Capital Increase Due To Modification
AdjustmentsToAdditionalPaidInCapitalIncreaseDueToModification
197000
CY2016 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
270000
CY2016 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
172000
CY2016 us-gaap Depreciation And Amortization
DepreciationAndAmortization
304000
CY2015 us-gaap Depreciation And Amortization
DepreciationAndAmortization
294000
CY2016 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-4000
CY2015 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
10000
CY2016 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
140000
CY2015 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
85000
CY2015 rkda Payment Of Research And Develop Fees With Cost Investment
PaymentOfResearchAndDevelopFeesWithCostInvestment
500000
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
1059000
CY2015 us-gaap Share Based Compensation
ShareBasedCompensation
1392000
CY2015 rkda Change In Fair Value Of Derivative Liabilities Related To Convertible Promissory Notes
ChangeInFairValueOfDerivativeLiabilitiesRelatedToConvertiblePromissoryNotes
9000
CY2015 rkda Gain On Expiration Of Warrant And Derivative Liability Related To Notes Payable
GainOnExpirationOfWarrantAndDerivativeLiabilityRelatedToNotesPayable
437000
CY2016 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
198000
CY2015 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
837000
CY2015 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-49000
CY2016 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-19000
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-357000
CY2015 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-336000
CY2016 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
102000
CY2015 us-gaap Increase Decrease In Unbilled Receivables
IncreaseDecreaseInUnbilledReceivables
-298000
CY2016 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-582000
CY2015 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-412000
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
185000
CY2015 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
415000
CY2016 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-5000
CY2015 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
125000
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
231000
CY2016 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
11000
CY2015 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-37000
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
215000
CY2015 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-821000
CY2016 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-17055000
CY2015 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-15109000
CY2015 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
10000
CY2016 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
41385000
CY2015 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
48719000
CY2015 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
151000
CY2016 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
36315000
CY2015 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
2500000
CY2016 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-5301000
CY2015 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-46360000
CY2015 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
68227000
CY2015 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
8205000
CY2015 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
45000000
CY2016 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
46000
CY2015 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
396000
CY2015 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
1319000
CY2016 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
442000
CY2015 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
360000
CY2015 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
8000000
CY2015 rkda Payments For Notes Payable And Convertible Promissory Notes
PaymentsForNotesPayableAndConvertiblePromissoryNotes
26796000
CY2016 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
396000
CY2015 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
68871000
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-21960000
CY2015 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7402000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16571000
CY2016 us-gaap Interest Paid
InterestPaid
1033000
CY2015 us-gaap Interest Paid
InterestPaid
2050000
CY2016 us-gaap Income Taxes Paid
IncomeTaxesPaid
29000
CY2015 us-gaap Income Taxes Paid
IncomeTaxesPaid
149000
CY2015 rkda Accretion Of Redeemable Convertible Preferred Stock
AccretionOfRedeemableConvertiblePreferredStock
2574000
CY2015 us-gaap Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
46000
CY2015 rkda Reclassification Of Deferred Initial Public Offering Costs To Equity
ReclassificationOfDeferredInitialPublicOfferingCostsToEquity
5022000
CY2015 rkda Issuance Of Warrants And Derivatives In Connection With Notes Payable Issuance
IssuanceOfWarrantsAndDerivativesInConnectionWithNotesPayableIssuance
437000
CY2015 rkda Stock Option Exercise Cost Included In Accounts Receivable
StockOptionExerciseCostIncludedInAccountsReceivable
1000
CY2015 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
85455000
CY2016 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;text-indent:5.24%;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:5.24%;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions in the Company&#8217;s consolidated financial statements and notes thereto. Significant estimates and assumptions made by management included the determination of the provision for income taxes, costs to complete government grants and research contracts, reserves for inventory, and the development period of revenue-generating technologies. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p></div>
CY2015 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.002
CY2016 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:8pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;text-indent:5.24%;">Concentration of Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:5.24%;">Cash and cash equivalents are maintained with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate its credit risks by spreading such risks across multiple counterparties and monitoring the risk profiles of these counterparties.</p></div>
CY2016 us-gaap Revenue Recognition Sales Of Goods
RevenueRecognitionSalesOfGoods
<div> <p style="margin-top:18pt;margin-bottom:0pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;text-indent:5.24%;">Product Revenues</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:5.24%;">Product revenues consist of sales of our SONOVA products. Product revenues are recognized once passage of title has occurred, contractually specified acceptance criteria have been met, and all other revenue recognition criteria have been met. Shipping and handling costs charged to customers are recorded as revenues and included in cost of product revenues at the time the sale is recognized.</p></div>
CY2016 us-gaap Revenue Recognition Services Licensing Fees
RevenueRecognitionServicesLicensingFees
<div> <p style="margin-top:18pt;margin-bottom:0pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;text-indent:5.24%;">License Revenues</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:5.24%;">The Company&#8217;s license agreements generally include up-front, nonrefundable license fees, annual license fees, and subsequent milestone payments. Upon commercialization of a product utilizing a licensed technology, the Company receives certain value-sharing payments associated with the incremental revenue attributable to the licensed technology.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has determined that, at the inception of each license agreement, there is only one deliverable for the license for, access to, and assistance with the development of the specified intellectual property. The up-front nonrefundable license fees are recognized as revenue proportionally over the development period, which approximates the expected efforts by the Company. The development period is estimated based upon factors such as type of traits, nature of crops and geographies, which are used to establish the initial deferral period. The Company continually reviews such estimates based on progress toward product commercialization and performs a thorough analysis at least annually. If the deferral period estimate changes, the amount of revenue recognized during the period is either accelerated or reversed to reflect the updated deferred balances as of the current period-end, capturing the cumulative effect of the changes. The annual license fees are payable at the end of the annual period and such fees typically are not required to be paid if the agreement is cancelled prior to the due date. Therefore, annual license fees are only recognized when they become due.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s license agreements generally include contingent milestone payments in the development life cycle of the related technology, such as achievement of specific technological targets, successful results from field trials, filing for approval with regulatory agencies, approvals granted by regulatory agencies and commercial launch of a product utilizing the licensed technology. The Company evaluates whether each milestone is substantive and at risk at the time the agreement is executed. This evaluation includes an assessment of whether (a)&#160;the consideration is commensurate with either (i)&#160;the entity&#8217;s performance to achieve the milestone or (ii)&#160;the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity&#8217;s performance to achieve the milestone; (b)&#160;the consideration relates solely to past performance; and (c)&#160;the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company generally considers non-refundable milestones that the Company expects to be achieved as a result of the Company&#8217;s efforts during the period of the Company&#8217;s performance obligations under the license agreement to be substantive and recognizes them as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once a product containing one or more of the Company&#8217;s traits is commercialized, the Company is entitled to receive a portion of the incremental revenue that the trait generates for its commercial partner. These value-sharing payments will be recorded on the accrual basis when results are reliably measurable, collectability is reasonably assured, and all other revenue recognition criteria are met. None have been received to date.</p></div>
CY2016 us-gaap Revenue Recognition Deferred Revenue
RevenueRecognitionDeferredRevenue
<div> <p style="margin-top:18pt;margin-bottom:0pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;text-indent:5.24%;">Unearned Revenue</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:5.24%;">The Company defers revenue to the extent that cash received in conjunction with a license agreement, contract or grant exceeds the revenue recognized in accordance with Company policies.</p></div>
CY2016 dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Arizona
CY2016 rkda Entity Incorporation Year Of Incorporation
EntityIncorporationYearOfIncorporation
2002
CY2016 rkda Entity Reincorporation State Country Name
EntityReincorporationStateCountryName
Delaware
CY2016 rkda Entity Reincorporation Date Of Reincorporation
EntityReincorporationDateOfReincorporation
2015-03
CY2016 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
one-for-four
CY2016 us-gaap Preferred Stock Conversion Basis
PreferredStockConversionBasis
At the closing of the IPO, all of the outstanding shares of convertible preferred stock and redeemable convertible preferred stock were automatically converted into 32,972,793 shares of common stock.
CY2015Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
32972793
CY2015Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2015Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2015Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2015Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2015Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2016 us-gaap Inventory Write Down
InventoryWriteDown
500000
CY2015 us-gaap Inventory Write Down
InventoryWriteDown
600000
CY2016Q4 rkda Inventory Raw Materials Current And Non Current
InventoryRawMaterialsCurrentAndNonCurrent
44000
CY2015Q4 rkda Inventory Raw Materials Current And Non Current
InventoryRawMaterialsCurrentAndNonCurrent
665000
CY2016Q4 rkda Inventory Finished Goods Current And Non Current
InventoryFinishedGoodsCurrentAndNonCurrent
1535000
CY2015Q4 rkda Inventory Finished Goods Current And Non Current
InventoryFinishedGoodsCurrentAndNonCurrent
1496000
CY2016Q4 rkda Inventory Current And Non Current Net
InventoryCurrentAndNonCurrentNet
1579000
CY2015Q4 rkda Inventory Current And Non Current Net
InventoryCurrentAndNonCurrentNet
2161000
CY2016 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2015 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2016Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5449000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5244000
CY2016Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4941000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4659000
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
52613000
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
19000
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
52594000
CY2015Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
67930000
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
197000
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
150000
CY2016 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
23
CY2016 us-gaap Other Restructuring Costs
OtherRestructuringCosts
0
CY2015Q4 us-gaap Long Term Debt
LongTermDebt
24930000
CY2015Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2015Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
24930000
CY2016 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
197000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
1000
CY2015Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
116000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
67815000
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2016 rkda Maturity Of Long Term Investments
MaturityOfLongTermInvestments
2018
CY2016Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
52594000
CY2015Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
67815000
CY2016 us-gaap Variable Interest Entity Terms Of Arrangements
VariableInterestEntityTermsOfArrangements
Both the Company and Bioceres incur expenses in support of specific activities agreed, as defined by joint work plans, which apply fair market value to each partner’s activities. Unequal contributions of services are equalized by the partners through cash payments. Verdeca is not the primary obligor for these activities performed by the Company or Bioceres. An agreement executed in conjunction with the formation of Verdeca specified that if Bioceres determines it requires cash to fund its contributed services (subject to certain annual limits), Bioceres, S.A. may elect to sell shares of its common stock to the Company for an amount not exceeding $5.0 million in the aggregate over a four-year period.
CY2016 rkda Contributed Services Period
ContributedServicesPeriod
P4Y
us-gaap Payments To Acquire Longterm Investments
PaymentsToAcquireLongtermInvestments
2000000
CY2014Q3 rkda Common Stock Shares Surrendered
CommonStockSharesSurrendered
1832
CY2015 rkda Research Agreement Settled
ResearchAgreementSettled
205000
CY2015Q4 us-gaap Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
632
CY2015Q4 us-gaap Fair Value Hedges At Fair Value Net
FairValueHedgesAtFairValueNet
500000
CY2015Q4 us-gaap Cost Method Investments
CostMethodInvestments
0
CY2016Q4 rkda Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
182000
CY2015Q4 rkda Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
323000
CY2016Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
170000
CY2015Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
157000
CY2016Q4 us-gaap Interest Payable Current
InterestPayableCurrent
98000
CY2015Q4 us-gaap Interest Payable Current
InterestPayableCurrent
9000
CY2016Q4 rkda Accrued Consulting Fees Current
AccruedConsultingFeesCurrent
29000
CY2015Q4 rkda Accrued Consulting Fees Current
AccruedConsultingFeesCurrent
152000
CY2016Q4 rkda Accrued Rent And Utilities Current
AccruedRentAndUtilitiesCurrent
85000
CY2015Q4 rkda Accrued Rent And Utilities Current
AccruedRentAndUtilitiesCurrent
77000
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
45000
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
57000
CY2016Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
0
CY2015Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
24000
CY2016 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2016 rkda Number Of Equity Incentive Plans
NumberOfEquityIncentivePlans
2
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3759839
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
352494
CY2016 rkda Milestones Payments Yet To Be Achieved
MilestonesPaymentsYetToBeAchieved
2000000
CY2015 rkda Milestones Payments Yet To Be Achieved
MilestonesPaymentsYetToBeAchieved
2000000
CY2016 rkda Milestones Payment
MilestonesPayment
0
CY2015 rkda Milestones Payment
MilestonesPayment
0
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-19599000
CY2015 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1300000
CY2016Q4 rkda Royalties On Licensed Revenue Accrued
RoyaltiesOnLicensedRevenueAccrued
201000
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.59
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.33
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.76
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.17
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.18
CY2015Q4 rkda Royalties On Licensed Revenue Accrued
RoyaltiesOnLicensedRevenueAccrued
177000
CY2015 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
609066
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
75758
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3427509
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1799395
CY2016 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
228141
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
419981
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4578782
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4561042
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2804796
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.00
CY2015 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
7.30
CY2016 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.49
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.38
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.37
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.65
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
12499000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3707000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1500000
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
0
CY2016 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
283000
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
730000
CY2016Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
1700000
CY2016 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M13D
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.13
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.64
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
782000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
334000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
5000
CY2016Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1121000
CY2016 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1300000
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-17930000
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
0
CY2015 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
0
CY2016 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2015 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2016 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1000
CY2015 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
2000
CY2016 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
24000
CY2015 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
24000
CY2016 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
25000
CY2015 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
26000
CY2016 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2016 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
8500000
CY2015 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2016 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2015 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2016 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2015 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2015 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2016 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2015 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2016 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.047
CY2015 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.045
CY2016 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.378
CY2015 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.368
CY2016 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.009
CY2015 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.018
CY2016 rkda Effective Income Tax Rate Reconciliation Withholding Taxes
EffectiveIncomeTaxRateReconciliationWithholdingTaxes
-0.001
CY2015 rkda Effective Income Tax Rate Reconciliation Withholding Taxes
EffectiveIncomeTaxRateReconciliationWithholdingTaxes
-0.001
CY2016 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.001
CY2016Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
49593000
CY2015Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
41807000
CY2016Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
1501000
CY2015Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
1421000
CY2016Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2861000
CY2015Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2485000
CY2016Q4 rkda Deferred Tax Assets Accrued Payroll And Benefits
DeferredTaxAssetsAccruedPayrollAndBenefits
215000
CY2015Q4 rkda Deferred Tax Assets Accrued Payroll And Benefits
DeferredTaxAssetsAccruedPayrollAndBenefits
226000
CY2016Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
143000
CY2015Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
106000
CY2016Q4 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
13000
CY2015Q4 us-gaap Deferred Tax Assets Capital Loss Carryforwards
DeferredTaxAssetsCapitalLossCarryforwards
16000
CY2016Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
191000
CY2015Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
192000
CY2016Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
1110000
CY2015Q4 us-gaap Deferred Tax Assets Inventory
DeferredTaxAssetsInventory
912000
CY2016Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
5000
CY2015Q4 us-gaap Deferred Tax Assets Charitable Contribution Carryforwards
DeferredTaxAssetsCharitableContributionCarryforwards
7000
CY2016Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
55632000
CY2015Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
47172000
CY2016Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
55632000
CY2015Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
47172000
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2015Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2015 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
6600000
CY2016 us-gaap Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
it has not forfeited the right to carryforward tax losses up to 20 years
CY2016 rkda Income Tax Examination Year Open Back Under Examination
IncomeTaxExaminationYearOpenBackUnderExamination
2000
CY2016Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2016 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2016 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.03
CY2016 us-gaap Description Of Defined Contribution Pension And Other Postretirement Plans
DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans
Employees’ rights to employer contributions vest on the one-year anniversary of their date of employment.
CY2016 rkda Defined Benefit Plan Contribution Vesting Period
DefinedBenefitPlanContributionVestingPeriod
P1Y
CY2016 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2015 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2016 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5915676
CY2015 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4764403

Files In Submission

Name View Source Status
0001564590-17-003724.txt Edgar Link pending
0001564590-17-003724-index-headers.html Edgar Link pending
0001564590-17-003724-index.html Edgar Link pending
0001564590-17-003724-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g2017030818294998427429.jpg Edgar Link pending
g2017030818295005327430.jpg Edgar Link pending
g2017030818295005727431.jpg Edgar Link pending
g2017030818295006327432.jpg Edgar Link pending
g2017030818295007327433.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rkda-10k_20161231.htm Edgar Link pending
rkda-20161231.xml Edgar Link completed
rkda-20161231.xsd Edgar Link pending
rkda-20161231_cal.xml Edgar Link unprocessable
rkda-20161231_def.xml Edgar Link unprocessable
rkda-20161231_lab.xml Edgar Link unprocessable
rkda-20161231_pre.xml Edgar Link unprocessable
rkda-ex311_6.htm Edgar Link pending
rkda-ex312_8.htm Edgar Link pending
rkda-ex321_9.htm Edgar Link pending
rkda-ex322_7.htm Edgar Link pending
Show.js Edgar Link pending